title: [Controlled clinical study of Consupren versus cyclophosphamide in chronic glomerulonephritis. II. Adverse effects].
abstract: BACKGROUND
  The second part of the study was designed to assess Consupren side effects.
  
  
  RESULTS
  The groups of patients studied were described in Part I. Side affects typical of Cy-A were evaluated only in the CS group. Gastrointestinal intolerance, only mild and temporary, was observed in 31%, neurotoxicity in 44%, hypertrichosis in 37%, nephrotoxicity in 25%, and gingival hypertrophy in 19%. Mean values of systolic and diastolic blood pressure did not change significantly in the course of treatment. When changes in blood pressure were individually investigated in particular patients, they were found in 31% in the CS group and in none in the K group. Mean values of uric acid non-significantly increased in the CS group and, on individual investigation, hyperuricaemia was observed in 31%. Mean values of serum potassium did not alter significantly. Signs of possible hepatotoxicity were found in 37% patients of the CS group. In this group, there was a significant decrease in haemoglobin mean values and a decrease in haemoglobin of more than 25 g/l was observed in 44% of CS group patients. In the K group significant decrease in mean leukocyte count was noted, but no patient developed real leukopenia.
  
  
  CONCLUSIONS
  The occurrence of side effects was comparable to data known from the literature.
authors.affiliation: IKEM, Praha.
authors.forename: I
authors.initials: I
authors.lastname: Matl
authors.forename: K
authors.initials: K
authors.lastname: Matousovic
authors.forename: V
authors.initials: V
authors.lastname: Herout
authors.forename: K
authors.initials: K
authors.lastname: Konecný
authors.forename: A
authors.initials: A
authors.lastname: Kovác
authors.forename: I
authors.initials: I
authors.lastname: Rychlík
authors.forename: D
authors.initials: D
authors.lastname: Sobotová
authors.forename: R
authors.initials: R
authors.lastname: Roland
authors.forename: I
authors.initials: I
authors.lastname: Zdichyncová
authors.forename: V
authors.initials: V
authors.lastname: Lánská
mesh_terms: D002908:Chronic Disease; D003520:Cyclophosphamide / Q000009:adverse effects* / Q000627:therapeutic use; D016572:Cyclosporine / Q000009:adverse effects* / Q000627:therapeutic use; D005921:Glomerulonephritis / Q000188:drug therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D007166:Immunosuppressive Agents; D016572:Cyclosporine; D003520:Cyclophosphamide